Summary hub: colorectal cancer, cecal cancer, sigmoid cancer, rectal cancer, and anal cancer
Colorectal cancer encompasses malignant tumors of all sections of the large intestine—from the cecum and ascending colon to the sigmoid and rectum, as well as anal cancer as a distinct form. At the Ichilov (Sourasky) Medical Center in Tel Aviv, this area is managed by an oncogastroenterology team: colorectal surgeons, oncologists, radiotherapists, gastroenterologists, pathomorphologists, and geneticists. The strategy is formed at an interdisciplinary Tumor Board after precise staging according to TNM and molecular profiling (KRAS, NRAS, BRAF, MSI/dMMR, HER2).
Diagnosis begins with high-resolution colonoscopy with NBI and chromoendoscopy; if findings are present, targeted biopsy and polyp removal using EMR/ESD are performed. Staging utilizes high-resolution pelvic MRI (mandatory for rectal cancer), PET-CT, and tumor markers CEA, CA 19-9. Molecular testing directly influences the choice of systemic therapy: MSI-high patients receive first-line immunotherapy, BRAF-mutant patients receive combinations of targeted therapies, and HER2+ patients receive trastuzumab.
Surgical arsenal includes laparoscopic and robot-assisted (da Vinci) resections of the colon, TaTME for rectal cancer, organ-preserving surgeries with sphincter preservation, cytoreductive interventions with HIPEC for peritoneal carcinomatosis, and treatment of liver metastases in conjunction with the hepatobiliary team (RFA, resection, TACE). Pharmacological therapy is based on FOLFOX/FOLFIRI, modern targeted therapies (bevacizumab, cetuximab, panitumumab), immunotherapy for MSI-high, and radiotherapy—from neoadjuvant courses to total neoadjuvant therapy (TNT) for rectal cancer.
This hub consolidates articles on all localizations of colorectal cancer (colon, sigmoid, cecum, small and rectum, anal cancer), as well as diagnostic programs and specialized physicians at the Sourasky clinic.